Literature DB >> 18932051

Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer.

Gunnar Ronquist1, Goran Frithz, Yu-Hui Wang, Torsten Lindeborg.   

Abstract

OBJECTIVE: A prior report suggested that individuals medicated with captopril showed a decreased incidence of prostate cancer. This study therefore investigated whether captopril given postoperatively had any preventive effect on biochemical recurrence for patients treated with radical prostatectomy.
MATERIAL AND METHODS: Data were prospectively reviewed for 62 men subjected to radical retropubic prostatectomy due to biopsy-confirmed, clinically localized prostate cancer and comparisons were made between two groups, those receiving captopril postoperatively (12.5 mg twice daily; captopril group, n=32) and those not receiving any captopril (control group, n=30). One surgeon carried out the surgery.
RESULTS: The two groups were comparable as regards age at surgery, prostate volume, preoperative prostate-specific antigen values, pathological stage, Gleason score, organ-confined disease, occurrence of positive surgical margins and extraprostatic extension. The incidence of biochemical failure was three out of 32 patients in the captopril group and 10 out of 30 in the control group (p=0.034) during a mean observational time of 29 months.
CONCLUSIONS: A lower rate of biochemical recurrence was observed in men subjected to radical prostatectomy treated with captopril postoperatively than in those not receiving captopril. These results were based on only 32 observations; a larger study may show no evidence of an association.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18932051     DOI: 10.1080/00365590802468875

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  11 in total

1.  Angiotensin and systems thinking: wrapping your mind around the big picture.

Authors:  Gary Robert Smith
Journal:  Ochsner J       Date:  2013

2.  Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts.

Authors:  Chris R Cardwell; Úna C Mc Menamin; Blánaid M Hicks; Carmel Hughes; Marie M Cantwell; Liam J Murray
Journal:  BMC Med       Date:  2014-02-13       Impact factor: 8.775

Review 3.  Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies.

Authors:  Hong Sun; Tao Li; Rongyuan Zhuang; Weimin Cai; Yuanting Zheng
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

4.  Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.

Authors:  Aino Siltari; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen
Journal:  PLoS One       Date:  2020-06-29       Impact factor: 3.240

5.  Impact of Metabolic Syndrome Diagnosis and Its Treatment on Survival of Colorectal Cancer Patients.

Authors:  Rose N Mafiana; Maimona S Al-Kindi; Ngozichukwu Mafiana; Ahmed S Al Lawati; Mansour Al Moundhri
Journal:  J Cancer Epidemiol       Date:  2019-04-21

6.  Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.

Authors:  Yonghui Wu; Jeremy L Warner; Liwei Wang; Min Jiang; Jun Xu; Qingxia Chen; Hui Nian; Qi Dai; Xianglin Du; Ping Yang; Joshua C Denny; Hongfang Liu; Hua Xu
Journal:  JCO Clin Cancer Inform       Date:  2019-05

Review 7.  Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System.

Authors:  Imogen M Roth; Agadha C Wickremesekera; Susrutha K Wickremesekera; Paul F Davis; Swee T Tan
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

8.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

9.  Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.

Authors:  Lili Miao; Wei Chen; Ling Zhou; Huanying Wan; Beili Gao; Yun Feng
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

Review 10.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.

Authors:  Matthias Pinter; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2017-10-04       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.